Bayer (BAYRY) announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk ischemic attack. There was no increase in the risk of ISTH major bleeding in patients treated with asundexian compared to placebo, both in combination with antiplatelet therapy. Detailed results of OCEANIC-STROKE will be presented at an upcoming scientific congress.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer announces FDA approval of Hyrnuo for non-small cell lung cancer
- FDA grants accelerated approval to sevabertinib for non-squamous non-small cell
- Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers
- Bayer price target raised to EUR 30.40 from EUR 26 at Berenberg
- Bayer AG Earnings Call: Growth Amid Challenges